UK markets open in 29 minutes
NIKKEI 225
37,552.16 +113.55 (+0.30%) HANG SENG
16,773.22 +261.53 (+1.58%) CRUDE OIL
83.02 +0.17 (+0.21%) GOLD FUTURES
2,315.00 -31.40 (-1.34%) DOW
38,239.98 +253.58 (+0.67%) Bitcoin GBP
54,036.55 +259.74 (+0.48%)
Arrowhead Pharmaceuticals, Inc. (ARWR)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 2.96B |
| Enterprise value | 2.86B |
| Trailing P/E | 478.56 |
| Forward P/E | 111.11 |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 14.10 |
| Price/book (mrq) | 18.48 |
| Enterprise value/revenue | 15.75 |
| Enterprise value/EBITDA | -10.66 |
Trading information
Stock price history
| Beta (5Y monthly) | 0.72 |
| 52-week change 3 | -28.77% |
| S&P500 52-week change 3 | 23.06% |
| 52-week high 3 | 42.48 |
| 52-week low 3 | 20.67 |
| 50-day moving average 3 | 28.66 |
| 200-day moving average 3 | 29.25 |
Share statistics
| Avg vol (3-month) 3 | 1.26M |
| Avg vol (10-day) 3 | 931.16k |
| Shares outstanding 5 | 123.9M |
| Implied shares outstanding 6 | 123.9M |
| Float 8 | 118.95M |
| % held by insiders 1 | 4.49% |
| % held by institutions 1 | 66.06% |
| Shares short (28 Mar 2024) 4 | 8.87M |
| Short ratio (28 Mar 2024) 4 | 5.77 |
| Short % of float (28 Mar 2024) 4 | 8.40% |
| Short % of shares outstanding (28 Mar 2024) 4 | 7.16% |
| Shares short (prior month 29 Feb 2024) 4 | 8.84M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 1:10 |
| Last split date 3 | 17 Nov 2011 |
Financial highlights
Fiscal year
| Fiscal year ends | 30 Sept 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | -163.32% |
| Operating margin (ttm) | -3,845.25% |
Management effectiveness
| Return on assets (ttm) | -24.66% |
| Return on equity (ttm) | -106.24% |
Income statement
| Revenue (ttm) | 181.74M |
| Revenue per share (ttm) | 1.70 |
| Quarterly revenue growth (yoy) | -94.30% |
| Gross profit (ttm) | N/A |
| EBITDA | -285.35M |
| Net income avi to common (ttm) | -296.81M |
| Diluted EPS (ttm) | -2.77 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 213.38M |
| Total cash per share (mrq) | 1.72 |
| Total debt (mrq) | 392.27M |
| Total debt/equity (mrq) | 225.81% |
| Current ratio (mrq) | 3.73 |
| Book value per share (mrq) | 1.49 |
Cash flow statement
| Operating cash flow (ttm) | -196.21M |
| Levered free cash flow (ttm) | -317.24M |
© 2024 Yahoo. All rights reserved.